本研究旨在评估左心室射血分数（LVEF）降低的肺癌患者的临床结果。本研究纳入了2010至2018年接受肺部切除术的9814名肺癌患者。其中，56名（0.57％）患者的LVEF等于或小于45％。我们进行了倾向性评分匹配（1：3），以比较56名（降低LVEF组）患者的术后临床结果和生存率与168名正常LVEF患者（非降低LVEF组）的差异。将降低LVEF组和非降低组的数据进行匹配并进行比较。降低LVEF组的30天（1.8％）和90天（7.1％）死亡率均高于非降低LVEF组（30天和90天死亡率均为0％）（p＜0.001）。在非降低LVEF组（66.0％）和降低LVEF组（60.1％）中，5年总生存率估计率相似。对于临床第1期肺癌，非降低LVEF组和降低LVEF组的5年总生存率估计率几乎相同（分别为76.8％和76.4％），但对于第2和第3期，非降低LVEF组的5年总生存率估计率显著优于降低LVEF组（分别为53.8％ vs.39.8％）。对于选择的降低LVEF患者进行肺癌手术可以获得有利的长期结果，尽管早期死亡率相对较高。精选患者和细致的术后护理可以进一步改善降低LVEF的临床结果。©作者（2023年）由牛津大学出版社代表欧洲胸心外科学会出版。版权所有。

The aim of the study was to evaluate the clinical outcomes of patients with lung cancer in whom left ventricular ejection fraction (LVEF) was reduced.9814 patients with lung cancer who underwent pulmonary resection from 2010 to 2018 were included for the study. Fifty-six (0.57%) patients had LVEFs equal or less than 45% and we performed propensity-score matching (1:3) to compare postoperative clinical outcomes and survival in 56 patients (reduced LVEF group) with those in 168 patients with normal LVEFs (nonreduced LVEF group).The data of the reduced LVEF group and nonreduced group were matched and compared. The 30- (1.8%) and 90-day (7.1%) mortality rates were higher in the reduced LVEF group than those (0% for both 30- and 90-day mortality rates) in the nonreduced LVEF group (p < 0.001). The estimated rates of overall survival at 5-year point were similar in the non-reduced LVEF group (66.0%) and in the reduced LVEF group (60.1%). The estimated rates of overall survival at 5-year point were almost the same between in the nonreduced and reduced LVEF groups for clinical stage 1 lung cancer (76.8% vs 76.4%, respectively), but for stages 2 and 3, they were significantly better in the nonreduced LVEF group than in the reduced LVEF group (53.8% vs.39.8%, respectively).Lung cancer surgery for selected patients with reduced LVEFs can yield favorable long-term outcomes despite the relatively high early mortality rate. A careful patient selection and meticulous postoperative care could further improve clinical outcome with reduced LVEF.© The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.